-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

732.Oral Section II 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Novel Approaches to Risk Stratification and Optimization for Transplant

Symposia: Allogeneic Transplantation: Disease Response and Comparative Treatment Studies Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Adult, Acute Myeloid Malignancies, AML, Combination therapy, Lymphoid Leukemias, ALL, Acquired Marrow Failure Syndromes, Translational Research, Epidemiology, Bispecific Antibody Therapy, Bone Marrow Failure Syndromes, Clinical Research, Health outcomes research, Pediatric, Diseases, Therapy sequence, Immune mechanism, Biological therapies, Treatment Considerations, Real-world evidence, Lymphoid Malignancies, Myeloid Malignancies, Biological Processes, Microbiome, Emerging technologies, Technology and Procedures, Study Population, Human, Measurable Residual Disease , Transplantation (Allogeneic and Autologous), Omics technologies
Monday, December 9, 2024: 10:30 AM-12:00 PM
Room 6A (San Diego Convention Center)
Moderators:
Meng Lv, MD, PhD, Peking University Institute of Hematology and Andrew Artz, MD, MS, City of Hope National Medical Center
Disclosures:
Artz: Astra Zeneca: Honoraria; Daichii Sankyo: Consultancy; Abbvie: Consultancy.

In this section, we have focused on refining HCT practice by precise stratification. This includes predicting outcomes through intestinal microbiome recovery, forecasting post-transplant relapse in MDS, personalizing treatment choices, determining the optimal timing for HCT in R/R AML, maintaining therapy after transplantation in FLT3+ AML, and deciding whether allo-HCT is necessary for MRD(-) CR1 ALL. We hope the ASH audience will appreciate and benefit from this section, learning how to refine prediction and therapy in HCT through emerging molecular techniques and target therapies.
10:30 AM

Srideshikan Sargur Madabushi, PhD1, Ji Eun Lim, PhD1*, Yu-Lin SU, PhD2*, Paresh Vishwasrao1,3*, Dongyun Yang, PhD4*, James F. Sanchez, PhD5*, Sally Mokhtari, PhD5, Amandeep Salhotra, MD6, Xiwei Wu, PhD, MD7,8*, Haiqing Lee8*, Savita Dandapani, MD, PhD1*, Ryotaro Nakamura, MD6, Raju Pillai, MD9*, Marcin Kortylewski, PhD2*, Jeffrey Wong, MD1*, Monzr M. Al Malki, MD6, Anthony S. Stein, MD6 and Susanta Hui, PhD1*

1Radiation Oncology, City of Hope National Medical Center, Duarte, CA
2Department of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA
3Division of Pediatric Hematology, Oncology, and Bone Marrow Transplantation, University of Wisconsin-Madison, Madison
4Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA
5Clinical and Translational Project Development, City of Hope National Medical Center, Duarte, CA
6Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
7Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA
8Integrated Genomic Core, City of Hope National Medical Center, Duarte, CA
9Department of Pathology, City of Hope National Comprehensive Cancer Center, Duarte, CA

10:45 AM

Matthias Stelljes, MD1, Jan Moritz Middeke, MD2*, Gesine Bug, MD3*, Eva-Maria Wagner Drouet4*, Lutz Peter Hermann Mueller, MD5*, Christoph Schmid, MD6*, Stefan W. Krause, MD7*, Wolfgang Andreas Bethge, MD8*, Edgar Jost, MD9*, Uwe Platzbecker, MD10, Stefan Klein, MD11, Judith Niederland, MD12*, Martin Kaufmann, MD13, Kerstin Schäfer-Eckart, MD14*, Henning Baldauf, M.Sc.15*, Friedrich Stölzel16*, Sarah Trost, M.Sc.15*, Christoph Röllig, MD17*, Malte von Bonin, MD18*, Katharina Egger-Heidrich, MD19*, Désirée Kunadt2*, Björn Steffen, MD20*, Beate Hauptrock, MD21*, Christoph Schliemann, MD22*, Katja Sockel, MD23*, Fabian Lang, MD24*, Oliver Kriege, MD25*, Judith Schaffrath, MD26*, Christian Reicherts, MD27*, Wolfgang E. Berdel, MD28, Hubert Serve, MD29, Gerhard Ehninger, M.D.30,31, Alexander H. Schmidt, MD32*, Jan-Henrik Mikesch, MD27*, Martin Bornhäuser, MD23,33* and Johannes Schetelig, MD, MSc15,17

1Department of Medicine A (Hematology, Hemostaseology, Oncology, Pneumology), University of Muenster, Muenster, Germany
2Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
3Department of Medicine 2, Goethe University Frankfurt, Frankfurt, Germany
4Medical Clinic III, University Medical Center Mainz, Mainz, Germany
5Department of Internal Medicine IV, University Hospital Halle Martin Luther, University Halle-Wittenberg, Halle, Germany
6Department of Hematology, University Hospital Augsburg, Augsburg, Germany
7Medical Clinic V, University Clinic Erlangen, Erlangen, Germany
8Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Tübingen, Germany
9University Hospital Aachen & Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Aachen, Germany
10Department for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany
11Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
12Clinic for Haematology and Celltherapie, Helios Clinic Berlin-Buch, Berlin, DEU
13Department of Hematology, Oncology and Palliative Care, Robert Bosch Hospital, Stuttgart, Germany
14Department of Internal Medicine V, Paracelsus University Hospital Nuremberg, Nuremberg, Germany
15Clinical Trials Unit, DKMS Group gGmbH, Dresden, Germany
16Division of Stem Cell Transplantation and Cellular Immunotherapies, University Hospital Schleswig-Holstein, Kiel, Germany
17Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Saxony, Germany
18University Hospital Carl Gustav Carus Technical University Dresden, Dresden, Germany
19Department of Internal Medicine 1, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
20Goethe-University Frankfurt, University Hospital, Department of Medicine II - Hematology and Oncology, Frankfurt am Main, Germany
21Department of Internal Medicine III, University Medical Center Mainz, Mainz, Germany
22Department of Medicine A, University Hospital Muenster, Muenster, Germany
23University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
24Department of Medicine, Hematology/Oncology, Goethe University Frankfurt, University Hospital, Frankfurt/Main, Germany
25Department of Internal Medicine III, University Hospital Medical Center Mainz, Mainz, Germany
26Department of Internal Medicine IV, Hematology and Oncology, Martin Luther University Halle-Wittenberg, Halle, Germany
27Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany
28Department of Medicine A (Hematology, Hemostaseology, Oncology, Pneumology), University Hospital Muenster, Muenster, Germany
29Department of Medicine, Hematology/Oncology, Goethe-University Frankfurt, University Hospital, Frankfurt am Main, Germany
30Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, DEU
31Cellex Cell Professionals GmbH, Cologne, Germany, Cologne, Germany
32DKMS Group gGmbH, Dresden, Germany
33National Center for Tumor Diseases Dresden (NCT/UCC), Technical University Dresden, Dresden, Germany

11:00 AM

Benjamin Kroger, BS1, Roni Tamari, MD2, Carmelo Gurnari, MD, PhD3, Julio Alvarenga Thiebaud, MD1,4, Alejandro Marinos Velarde, MD1,4, Yazan F Madanat, MD1,4, Robert H. Collins, MD1,4, Clayton Jackson, MD1,4*, Vivian Irizarry Gatell, MD1,4, Valeria Visconte, PhD5, Jaroslaw Maciejewski6, David Sallman, MD7 and Stephen Chung, MD1,4,8

1Division of Hematology/Oncology, Department of Internal Medicine, University of Texas Southwestern, Dallas, TX
2Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY
3Cleveland Clinic Foundation, Cleveland, OH
4Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX
5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Taussig Cancer Institute, Cleveland, OH
6Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
7Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
8Children's Research Institute, University of Texas Southwestern, Dallas, TX

11:15 AM

Yomna Eissa1*, Hyeoung-Joon Kim, MD, PhD2, Joon Ho Moon, MD, PhD3*, Robert Zeiser, MD4, Francesca Biavasco4*, Christopher Lemieux, MD5, Mohamed Elemary, MD, MSc, PhD6*, Varun Mehra, FRCPATH, MRCP7*, Mili Shah7*, Ahmed Alotaibi8*, Yu Cai9*, Xianmin Song9, Jae-Sook Ahn, MD, PhD10, Sang Kyun Sohn, MD, PhD3*, Mohsen Al Zahrani11*, Muhned Alhumaid12*, Hee-Je Kim13 and Dennis Dong Hwan Kim, MD, PhD1

1Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada
2Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of (South)
3Kyungpook National University Hospital, Daegu, Korea, Republic of (South)
4University of Freiburg Medical Centre, Department of Medicine I, Freiburg, Germany
5Centre intégré de cancérologie, CHU de Québec - Université Laval, Québec, QC, Canada
6Provincial Hematology and Blood and Marrow Transplant Program, Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon, SK, Canada
7Dept. of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, United Kingdom
8King Faisal Specialist Hospital and Research, Cancer Center of Excellence, Riyadh, Saudi Arabia
9Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
10Chonnam National University Hwasun Hospital, Jeollanam-Do, Korea, Republic of (South)
11Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia
12Medical City, Riyadh, Saudi Arabia
13Department of Hematology, Seoul St. Mary's Hospital, Seoul, Korea, Republic of (South)

11:30 AM

Michaela Liedtke, MD1, Zhuoxin Sun, PhD2*, Mark R. Litzow, MD3, Ryan J Mattison, MD4, Elisabeth Paietta, PhD5*, Kathryn G. Roberts6*, Yanming Zhang, MD7, Janis Racevskis, PhD8*, Hillard M. Lazarus, MD9, Jacob M. Rowe, MD10, Daniel A. Arber, MD11, Julie Bergeron, MD12*, Brent L. Wood, MD, PhD13, Yaqi Zhao, MSc14*, Gang Wu, PhD14*, Ti-Cheng Chang, PhD14*, Wenchao Zhang, PhD14*, Keith W. Pratz, MD15, Shira N. Dinner, MD16, Noelle Frey, MD, MS17, Steven D. Gore, MD18, Bhavana Bhatnagar, DO19, Ehab L. Atallah, MD20, Geoffrey L. Uy, MD21, Deepa Jeyakumar, MD22, Tara L. Lin, MD23, Cheryl L. Willman, MD24*, Daniel J. DeAngelo, MD, PhD25, Shejal B. Patel, DO26, Michelle A Elliott, MD24, Anjali S. Advani, MD27, Dimitrios Tzachanis, MD, PhD28, Pankit Vachhani, MD29*, Rupali Bhave, MD30*, Elad Sharon, MD, MPH31*, Richard F. Little, MD, MPH32, Harry P. Erba, MD, PhD33, Richard M. Stone, MD25, Selina Luger, MD, FRCPC34, Charles G. Mullighan, MBBS, MSc, MD6, Martin S. Tallman, MD35 and Matthew J. Wieduwilt, MD36*

1Stanford University Cancer Center, Stanford, CA
2Dana-Farber Cancer Institute, Boston, MA
3Division of Hematology, Mayo Clinic, Rochester, MN
4Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI
5Department of Oncology, Montefiore Medical Center, Bronx, NY
6Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
7Cytogenetics Laboratory, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
8Montefiore Medical Center, Bronx, NY
9Case Western Reserve University, Cleveland, OH
10Shaare Zedek Medical Center, Jerusalem, Israel
11University of Chicago, Chicago, IL
12Hopital Necker Enfants Malades, Paris, FRA
13Department of Laboratory Medicine, Seattle Cancer Care Alliance, Los Angeles, CA
14St. Jude Children's Research Hospital, Memphis, TN
15Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
16Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
17University of Pennsylvania, Philadelphia, PA
18National Cancer Institute, National Institutes of Health, Rockville, MD
19West Virginia University, Wheeling Hospital, Wheeling, WV
20Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
21Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO
22Department of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Health, University of California Irvine, Orange, CA
23Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Westwood, KS
24Mayo Clinic, Rochester, MN
25Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
26Virginia Commonwealth Univ/Massey Cancer Center, Richmond, VA
27Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
28UCSD Moores Cancer Center, Carlsbad, CA
29Roswell Park Comprehensive Cancer Center, Buffalo, NY
30Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC
31Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD
32National Cancer Institute, National Institutes of Health, Bethesda, MD
33Duke University Cancer Institute, Durham, NC
34Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA
35Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Highland Park, IL
36Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC

11:45 AM

Alix Schwarz1*, Tina Eismann1*, Tingting Zheng2*, Sophia Goeldel1*, Mats Urban1*, Mohsen Pourjam2*, Klaus Neuhaus2*, Ilias Lagkouvardos2*, Daniel Wolff, MD3*, Peter Herhaus, MD4*, Mareike Verbeek, MD4*, Ernst Holler, MD, PhD3*, Wolfgang Herr, MD3, Karin Kleigrewe5*, Simon M Heidegger, M.D1,6*, Klaus-Peter Janssen7*, Florian Bassermann, MD1,6,8*, Melanie Schirmer2*, Hendrik Poeck, MD3, Daniela Weber3* and Erik Thiele Orberg, MD, PhD3*

1Hospital Rechts der Isar, Internal Medicine III - Hematology and Oncology, Technical University of Munich, Munich, Germany
2ZIEL – Institute for food and health, Technical University of Munich, Freising, Germany
3Internal Medicine III - Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany
4Department of Medicine III, Hematology and Oncology, Technical University of Munich (TUM), School of Medicine and Health, Munich, Germany
5Bavarian Center for Biomolecular Mass Spectrometry, Technical University of Munich, Freising, Germany
6TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany
7Hospital Rechts der Isar, Department of Surgery, Technical University of Munich, Munich, Germany
8German Cancer Consortium (DKTK), Heidelberg, Germany

*signifies non-member of ASH